Condition: Acute Lymphoblastic Leukemia (ALL) · Mantle Cell Lymphoma (MCL) · Large B-cell Lymphoma · Sponsor: FamiCordTx
One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the safety of intravenous IMP administration in patients diagnosed with refractory and relapsed CD19 + B cell neoplasms.
This description comes directly from the study's public registry record.
Natalia Żmijewska · +48 795 158 306 · n.zmijewska@famicordtx.com
Always discuss trial participation with your own doctor first.
| Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego - Centralny Szpital Kliniczny | Warsaw, Ul. Banacha 1a, Poland | Recruiting |
| Uniwersyteckie Centrum Kliniczne Gdańskiego Uniwersytetu Medycznego - Katedra i Klinika Hematologii i Transplantologii | Gdansk, Ul. Smoluchowskiego 17, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06593145